NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a biopharmaceutical company which develops, manufactures and markets specialty life-saving therapeutics, announces today that the company will soon start phase II clinical trials with the inhaled version of its Alpha-1 Antitrypsin (AAT) product to treat Bronchiectasis, a lung disease that results in the distortion of one or more of the conducting bronchi or airways, most often secondary to an infectious process. The study will be conducted using an eFlow® Electronic Nebulizer (PARI Pharma GmbH) optimized for delivery of Kamada’s AAT product.
